Protalix BioTherapeutics (PLX) Cash from Investing Activities Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.41% |
| Dec 31, 2025 | -16.51% |
| Sep 30, 2025 | -15.60% |
| Jun 30, 2025 | -10.32% |
| Mar 31, 2025 | 61.11% |
| Dec 31, 2024 | -250.67% |
| Sep 30, 2024 | 116.51% |
| Jun 30, 2024 | -13.63% |
| Mar 31, 2024 | -10.31% |
| Dec 31, 2023 | -43.44% |
| Sep 30, 2023 | -146.81% |
| Jun 30, 2023 | -13.28% |
| Mar 31, 2023 | 75.03% |
| Dec 31, 2022 | 171.56% |
| Sep 30, 2022 | 121.21% |
| Jun 30, 2022 | 20.31% |
| Mar 31, 2022 | -124.83% |
| Dec 31, 2021 | 174.80% |
| Sep 30, 2021 | 135.30% |
| Jun 30, 2021 | 86.56% |
| Mar 31, 2021 | -153.52% |
| Dec 31, 2020 | -28.24% |
| Sep 30, 2020 | 117.05% |
| Jun 30, 2020 | -1.56% |
| Mar 31, 2020 | -223.51% |
| Mar 31, 2019 | -0.05% |
| Dec 31, 2018 | 18.23% |
| Sep 30, 2018 | 11.46% |
| Jun 30, 2018 | 30.29% |
| Mar 31, 2018 | 13.80% |
| Dec 31, 2017 | 38.16% |
| Sep 30, 2017 | 32.36% |
| Jun 30, 2017 | -23.48% |
| Mar 31, 2017 | 19.78% |
| Dec 31, 2016 | 20.18% |
| Sep 30, 2016 | 42.26% |
| Jun 30, 2016 | 23.99% |
| Mar 31, 2016 | 35.62% |
| Dec 31, 2015 | 108.20% |
| Sep 30, 2015 | 34.33% |